FDA approves new drug to treat postpartum depression
SAN DIEGO (KUSI) – Postpartum depression affects an estimated one in nine new mothers after childbirth and the FDA has approved the first drug to treat it. It’s called Zulresso, it’s an intravenous infusion of brexanolone administered as a single, 60 hour IV drip. Without treatment, symptoms can last for months or years.
Sage Therapeutics — the company that developed the treatment — estimates the drug will cost between $20,000 to $35,000 per treatment. Insurance coverage is still being worked out.
Despite the high price tag, this new drug is welcome news for new mothers struggling with postpartum depression.
Psychotherapist Cara Fairfax is here to talk about this new treatment.
If you need more information from the Postpartum Heath Alliance call (619) 254-0023 or visit www.postpartumhealthalliance.org